(NaturalNews) Vaccines introduce a weakened form of a virus into the body in hopes that the person's immune system will begin developing antibodies against it. The antigens in vaccines don't always stimulate an immune response because the person's immune system might be too weak to respond effectively. This is true for many senior citizens. In addition, vaccines might not provide any benefits to infants because their immune systems aren't even fully developed.

A strong immune system, empowered with adequate Vitamin D and C, can respond better to the science of vaccines. Interestingly though, those with strong natural immune systems are the ones who can forgo vaccines altogether and face viruses naturally. Vaccines might provide reassurances, giving a strong immune system a test run or "rehearsal" against specific viruses, but vaccines aren't as important as advertised for conditions that are not life-threatening.

It should also be noted that flu vaccines are a shot in the dark. The FDA reminds the public that flu vaccines are made on speculation of the emergence of virus strains. "Antibody against one influenza virus type or subtype may confer limited or possibly no protection against another. Furthermore, antibody to one antigenic variant of influenza virus may not protect against a different antigenic variant of the same type or subtype," the FDA states.

Inflammatory adjuvant added to vaccines to force the body to respond to antigens

Knowing that people's immune systems might not be able to respond to the antigens in vaccines, the manufacturers of the vaccines add inflammatory chemicals called adjuvants to stimulate a response in the individual's immune cells. Many vaccines are formulated with an aluminum-based adjuvant. This is highly controversial, especially because aluminum has been implicated in Alzheimer's. How might this metal interfere with the normal functions of the cells, especially in repeated doses?

A new flu vaccine called Fluad has been manufactured without the aluminum adjuvant, but it is made with another toxic adjuvant called MF59, which is primarily squalene oil and surfactants. The MF59 adjuvant is an oil-in-water emulsion that generates uniform squalene oil droplets. With the addition of two non-ionic surfactants to the mixture, this squalene oil is stabilized and allowed to act as a delivery system for the antigens in the vaccine.

According to an FDA analysis of the adjuvant, the squalene oil "activates local cells to take up the co-injected HA antigens that are present in the aqueous phase of the emulsion." In this action, the squalene oil becomes a precursor of cholesterol and steroid hormones, allowing for the increase of antigen intake in cells. This emulsion, which causes inflammation in the cells, is being fast-tracked by the FDA for speedy approval. This vaccine is designed for seniors over age 65.

10 percent of vaccine subjects reported adverse events within 30 minutes of injection

The vaccine has been tested on about 1,000 healthy Americans over the age of 65. Several fully investigated adverse events have been reported, including the onset of chronic disease. Despite its shortcomings, the Fluad vaccine was sent through an accelerated licensing process on September 15, 2015, by the FDA Vaccines and Related Biological Products Advisory Committee.

The President and co-founder of the non-profit National Vaccine Information Center (NVIC), Barbara Loe Fisher, is speaking out against the fast tracked Fluad vaccine.

"Novartis failed to demonstrate that squalene adjuvanted Fluad was more effective or safer than an unadjuvanted influenza vaccine in the small clinical trial being used to justify accelerated licensure. In fact, Fluad was shown to be far more reactive and, in some studies, the vaccine was associated with even more serious reactions in the elderly when given a second time," she stated.

According to the FDA analysis, 10 percent of healthy participants who took the squalene-based vaccine reported adverse events within 30 minutes of injection. These adverse events included pain, erythema, fever, chills, myalgia, arthralgia, headache, nausea, vomiting and diarrhea. After vaccination, 11 participants reported severe, incapacitating pain that stopped them from performing their usual activities. Thirty-eight people who took the Fluad shot developed nasopharyngitis between days one and 21 after vaccine administration. Why is this kind of faulty medicine being approved and fast-tracked, especially for use in seniors?

With an estimated 170 million doses of influenza vaccine set to be delivered to the U.S. market for the 2015-2016 flu season, the adverse effects of the toxic Fluad vaccine will be felt throughout the country.

Sources for this article include:
HealthImpactNews.com
FDA.gov